Dexcom (DXCM) Stock Forecast & Price Target

Compare

4,222 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

DXCM Analyst Ratings

Strong Buy

18 Buy

4 Hold

0 Sell

Based on 22 analysts giving stock ratings to

Dexcom

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

DXCM Stock 12 Month Forecast

Average Price Target

$100.89

▲(49.58% Upside)

Based on 22 Wall Street analysts offering 12 month price targets for Dexcom in the last 3 months. The average price target is $100.89 with a high forecast of $112.00 and a low forecast of $89.00. The average price target represents a 49.58% change from the last price of $67.45.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"65":"$65","77":"$77","89":"$89","101":"$101","113":"$113"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":112,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$112.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":100.89,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$100.89</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":89,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$89.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[65,77,89,101,113],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,74.3,77.2,80.1,83,85.9,88.8,91.7,94.6,97.5,100.4,103.3,106.2,109.1,{"y":112,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,74.3,76.34538461538462,78.39076923076922,80.43615384615384,82.48153846153846,84.52692307692308,86.57230769230769,88.61769230769231,90.66307692307691,92.70846153846153,94.75384615384615,96.79923076923077,98.84461538461538,{"y":100.89,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,74.3,75.43076923076923,76.56153846153846,77.6923076923077,78.82307692307693,79.95384615384616,81.08461538461538,82.21538461538461,83.34615384615384,84.47692307692307,85.6076923076923,86.73846153846154,87.86923076923077,{"y":89,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":69.34,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.35,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.31,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.77,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86.83,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.37,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.32,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.26,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.51,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":83.58,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.28,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.3,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$112.00

Average Price Target$100.89

Lowest Price Target$89.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Lila Implantra

TR | OpenAI - 4o

$87→$75

Buy

11.19%

Upside

Reiterated

09/20/25

AI Generated ArticleAI Generated Article

Brandon Vazquez

William Blair

―

Buy

―

Reiterated

09/19/25

Optimistic Buy Rating for Dexcom Amid Growth Potential and Addressed ConcernsWe downloaded millions of FDA MAUDE filings to analyze DexCom G7 trends given recent concerns about quality. We believe there are two key points investors need to keep in mind when doing this analysis: 1) the MAUDE database is incredibly noisy since anyone can file in it and most claims are not adjudicated, so the database is by no means definitive, and 2) in growth markets like this, we always need to assess MAUDE filings in the context of the rapid growth of users (i.e., we need to use a MAUDE filing per G7 user not a raw number of MAUDE filing analysis). As we looked at the data through this lens, we see there are some ebbs and flows of G7 MAUDE filings, but they line up with DexCom’s recent explanations, giving credence to its claims that it has fixed the issues and they will not impact its business going forward.

Josh Jennings

TD Cowen

$100

Buy

48.26%

Upside

Reiterated

09/18/25

Dexcom's Resilience: Addressing G7 Concerns and Achieving 2025 Targets

Joanne Wuensch

Citi

―

Buy

―

Reiterated

09/17/25

Citi Sticks to Their Buy Rating for Dexcom (DXCM)

Matthew O'Brien

Piper Sandler

$100

Buy

48.26%

Upside

Reiterated

09/12/25

Piper Sandler Remains a Buy on Dexcom (DXCM)Piper Sandler analyst Matt O\Brien reiterated an Overweight rating and $100.00 price target on DexCom (NASDAQ: DXCM).

Suraj Kalia

Oppenheimer

―

Hold

―

Downgraded

09/08/25

Dexcom (DXCM) was downgraded to a Hold Rating at OppenheimerWe are assuming coverage of DXCM and downgrading to a Perform rating from Outperform.

Lee Hambright

Bernstein

$98

Buy

45.29%

Upside

Reiterated

09/08/25

Bernstein Sticks to Their Buy Rating for Dexcom (DXCM)We rate ABT, BSX, DXCM, ISRG, MDT, SYK, and PODD Outperform.

Steven Silver

Argus Research

$100

Buy

48.26%

Upside

Initiated

08/21/25

DexCom initiated with a Buy at ArgusDexCom initiated with a Buy at Argus

Matthew Taylor

Jefferies

―

Buy

―

Reiterated

08/18/25

We reiterate our Buy rating on shares of DXCM, ABT, PODD, and TNDM, with a Hold rating on MDT.

Larry Biegelsen

Wells Fargo

$98

Buy

45.29%

Upside

Reiterated

08/11/25

Wells Fargo Sticks to Their Buy Rating for Dexcom (DXCM)

William Plovanic

Canaccord Genuity

$106

Buy

57.15%

Upside

Reiterated

08/01/25

Dexcom (DXCM) Receives a Buy from Canaccord Genuity

Jayson Bedford

Raymond James

$99→$102

Buy

51.22%

Upside

Reiterated

07/31/25

Raymond James Sticks to Their Buy Rating for Dexcom (DXCM)Raymond James analyst Jayson Bedford raised the price target on DexCom (NASDAQ: DXCM) to $102.00 (from $99.00) while maintaining a Strong Buy rating.

Richard Newitter

Truist Financial

$102

Buy

51.22%

Upside

Reiterated

07/31/25

Analysts Offer Insights on Healthcare Companies: Wave Life Sciences (NASDAQ: WVE), Neurocrine (NASDAQ: NBIX) and Dexcom (NASDAQ: DXCM)

Jeff Johnson

Robert W. Baird

$105→$112

Buy

66.05%

Upside

Reiterated

07/31/25

DexCom price target raised to $112 from $105 at BairdDexCom price target raised to $112 from $105 at Baird

Matt Miksic

Barclays

$93→$98

Hold

45.29%

Upside

Reiterated

07/31/25

Dexcom (DXCM) Receives a Hold from Barclays

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Lila Implantra

TR | OpenAI - 4o

$87→$75

Buy

11.19%

Upside

Reiterated

09/20/25

AI Generated ArticleAI Generated Article

Brandon Vazquez

William Blair

―

Buy

―

Reiterated

09/19/25

Josh Jennings

TD Cowen

$100

Buy

48.26%

Upside

Reiterated

09/18/25

Dexcom's Resilience: Addressing G7 Concerns and Achieving 2025 Targets

Joanne Wuensch

Citi

―

Buy

―

Reiterated

09/17/25

Citi Sticks to Their Buy Rating for Dexcom (DXCM)

Matthew O'Brien

Piper Sandler

$100

Buy

48.26%

Upside

Reiterated

09/12/25

Piper Sandler Remains a Buy on Dexcom (DXCM)Piper Sandler analyst Matt O\Brien reiterated an Overweight rating and $100.00 price target on DexCom (NASDAQ: DXCM).

Suraj Kalia

Oppenheimer

―

Hold

―

Downgraded

09/08/25

Dexcom (DXCM) was downgraded to a Hold Rating at OppenheimerWe are assuming coverage of DXCM and downgrading to a Perform rating from Outperform.

Lee Hambright

Bernstein

$98

Buy

45.29%

Upside

Reiterated

09/08/25

Bernstein Sticks to Their Buy Rating for Dexcom (DXCM)We rate ABT, BSX, DXCM, ISRG, MDT, SYK, and PODD Outperform.

Steven Silver

Argus Research

$100

Buy

48.26%

Upside

Initiated

08/21/25

DexCom initiated with a Buy at ArgusDexCom initiated with a Buy at Argus

Matthew Taylor

Jefferies

―

Buy

―

Reiterated

08/18/25

We reiterate our Buy rating on shares of DXCM, ABT, PODD, and TNDM, with a Hold rating on MDT.

Larry Biegelsen

Wells Fargo

$98

Buy

45.29%

Upside

Reiterated

08/11/25

Wells Fargo Sticks to Their Buy Rating for Dexcom (DXCM)

William Plovanic

Canaccord Genuity

$106

Buy

57.15%

Upside

Reiterated

08/01/25

Dexcom (DXCM) Receives a Buy from Canaccord Genuity

Jayson Bedford

Raymond James

$99→$102

Buy

51.22%

Upside

Reiterated

07/31/25

Richard Newitter

Truist Financial

$102

Buy

51.22%

Upside

Reiterated

07/31/25

Analysts Offer Insights on Healthcare Companies: Wave Life Sciences (NASDAQ: WVE), Neurocrine (NASDAQ: NBIX) and Dexcom (NASDAQ: DXCM)

Jeff Johnson

Robert W. Baird

$105→$112

Buy

66.05%

Upside

Reiterated

07/31/25

DexCom price target raised to $112 from $105 at BairdDexCom price target raised to $112 from $105 at Baird

Matt Miksic

Barclays

$93→$98

Hold

45.29%

Upside

Reiterated

07/31/25

Dexcom (DXCM) Receives a Hold from Barclays

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Dexcom

1 Month

xxx

Success Rate

14/25 ratings generated profit

Average Return

+2.78%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 56.00% of your transactions generating a profit, with an average return of +2.78% per trade.

3 Months

xxx

Success Rate

21/31 ratings generated profit

Average Return

+3.75%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 67.74% of your transactions generating a profit, with an average return of +3.75% per trade.

1 Year

Mathew BlackmanStifel Nicolaus

Success Rate

17/28 ratings generated profit

Average Return

+17.60%

reiterated a buy rating 5 months ago

Copying Mathew Blackman's trades and holding each position for 1 Year would result in 60.71% of your transactions generating a profit, with an average return of +17.60% per trade.

2 Years

xxx

Success Rate

18/31 ratings generated profit

Average Return

+27.72%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 58.06% of your transactions generating a profit, with an average return of +27.72% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

DXCM Analyst Recommendation Trends

Rating

May 25

Jun 25

Jul 25

Aug 25

Sep 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, DXCM has received 34 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. DXCM average Analyst price target in the past 3 months is 100.89.

Each month's total comprises the sum of three months' worth of ratings.

DXCM Financial Forecast

DXCM Earnings Forecast

Next quarter’s earnings estimate for DXCM is $0.57 with a range of $0.52 to $0.61. The previous quarter’s EPS was $0.48. DXCM beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.22% of the time in the same period. In the last calendar year DXCM has Outperformed its overall industry.

DXCM Sales Forecast

Next quarter’s sales forecast for DXCM is $1.18B with a range of $1.15B to $1.21B. The previous quarter’s sales results were $1.16B. DXCM beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.43% of the time in the same period. In the last calendar year DXCM has Outperformed its overall industry.

DXCM Stock Forecast FAQ

What is DXCM’s average 12-month price target, according to analysts?

Based on analyst ratings, Dexcom’s 12-month average price target is 100.89.

What is DXCM’s upside potential, based on the analysts’ average price target?

Dexcom has 49.58% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is DXCM a Buy, Sell or Hold?

Dexcom has a consensus rating of Strong Buy which is based on 18 buy ratings, 4 hold ratings and 0 sell ratings.

What is Dexcom’s price target?

The average price target for Dexcom is 100.89. This is based on 22 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $112.00 ,the lowest forecast is $89.00. The average price target represents 49.58% Increase from the current price of $67.45.

What do analysts say about Dexcom?

Dexcom’s analyst rating consensus is a Strong Buy. This is based on the ratings of 22 Wall Streets Analysts.

How can I buy shares of DXCM?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Dexcom (DXCM) Stock Forecast & Price Target

DXCM Analyst Ratings

DXCM Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Dexcom

DXCM Analyst Recommendation Trends

DXCM Financial Forecast

DXCM Earnings Forecast

DXCM Sales Forecast

DXCM Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts